{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.120","value":"-29.971"},{"groupId":"OG001","spread":"31.689","value":"-25.015"},{"groupId":"OG002","spread":"37.015","value":"-24.177"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"86"}],"units":"Participants"}],"description":"Smoking urges was measured on a 0 (not at all) - 100 (strongest feeling possible) scale. Higher values represent greater urge to smoke. Change in smoking urges was calculated as Follow-up score (6 month) - Baseline Score.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.\n\nvarenicline: Given orally","id":"OG000","title":"Arm I"},{"description":"Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.\n\nplacebo: Given orally","id":"OG001","title":"Arm II"},{"description":"Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.\n\nnicotine: Given transdermally and orally","id":"OG002","title":"Arm III"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"6 months","title":"Change in Smoking Urges","type":"SECONDARY","unitOfMeasure":"units on a scale"}